Degarelix for treating advanced hormone-dependent prostate cancer

  • Technology appraisal guidance
  • TA404
  • Published: 

Prostate cancer (advanced, hormone dependent) - degarelix depot: appeal announcement

Appeal Announcement

The Institute has received three appeals from:

  • Ferring Pharmaceuticals Ltd
  • British Uro-Oncology Group
  • Tackle Prostate Cancer

The appeal hearing was held at ETC Venues, Prospero House, 241 Borough High Street, London, SE1 1GA – Wednesday 25 June 2014 at 10am.

The Institute awaits the decision of the Appeal panel.

This page was last updated: 25 June 2014